The proposition that the hormone amylin functions in tandem with insulin in the control of blood glucose levels is still, as yet, a working hypothesis, said Pierre Lefebvre, of the Universitaire de Liege, Belgium, speaking at a satellite meeting of the 30th Annual Meeting of the European Association for the Study of Diabetes in Dusseldorf, Germany, last week. However, he added, Amylin Pharmaceuticals is making progress in testing the proposition.
Presenting data on its Phase II studies, Chris Moyses, vice president of clinical and regulatory affairs at Amylin Europe, said that the company's amylin analog, tripro-amylin (AC137), can improve post-prandial glucose control in patients with juvenile-onset diabetes. In the 14-day study, patients who continued their usual insulin therapy and self-injected tripro-amylin three times daily had lower average blood glucose levels after a test meal than did patients who received insulin plus placebo. After a 14-day period, a statistically-significant glucose smoothing effect was observed at 30ug and 100ug.
The drug is now in Phase IIb trials to investigate its effects in reducing hypoglycemia, and provide dose refinement and dose frequency efficacy data.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze